GRAIL

Overview

GRAIL, established in 2016 and subsequently acquired by Illumina, focuses on developing and commercializing technology for multi-cancer early detection (MCED). Its primary product, the Galleri test, utilizes a blood sample to detect more than 50 types of cancer across all stages, with a reported false positive rate of less than 1%. The test is designed for use in asymptomatic individuals over the age of 50, or other individuals at elevated risk for cancer, as an adjunct to standard single-cancer screenings like mammography or colonoscopy. It operates by analyzing cell-free DNA (cfDNA) fragments in the blood for genomic methylation patterns indicative of cancer signals. This approach aims to detect cancers at earlier stages when treatment may be more effective.

The Galleri test is deployed within a clinical context, requiring a healthcare professional's order. GRAIL's operational model emphasizes collaboration with healthcare systems and providers, supplying the diagnostic tool rather than direct patient interaction for testing. The company's work is supported by clinical studies, including the Circulating Cell-free Genome Atlas (CCGA) study and the PATHFINDER study, which have investigated the performance of cfDNA-based multi-cancer early detection tests in various populations. These studies have contributed to the understanding of MCED test characteristics, including sensitivity and specificity across different cancer types and stages. For example, the PATHFINDER study demonstrated the test's ability to detect a cancer signal, prompting diagnostic follow-up in a substantial percentage of participants with previously undetected cancer. The utility of MCED tests like Galleri is in identifying a cancer signal and predicting the tissue of origin, which then guides subsequent diagnostic evaluations by clinicians.

As an enterprise AI solution within healthcare, GRAIL's technology relies on machine learning algorithms trained on large datasets of genomic and epigenomic information. These algorithms interpret the complex patterns of cfDNA methylation to differentiate between cancer-derived and healthy cell-derived DNA. The company maintains a CLIA-certified laboratory for processing samples, ensuring adherence to clinical laboratory improvement amendments. While GRAIL's technology is primarily a diagnostic tool for healthcare providers, the underlying AI models represent an application of advanced bioinformatics and machine learning to a significant public health challenge.

Key features

• Multi-cancer early detection (MCED): Detects signals for over 50 types of cancer, many of which lack routine screening tests GRAIL clinical resources.
• Single blood draw: Utilizes a non-invasive blood sample for analysis.
• Proprietary methylation technology: Employs next-generation sequencing and machine learning to analyze cell-free DNA methylation patterns specific to cancer.
• High specificity: Designed to minimize false positives, with a reported specificity exceeding 99% GRAIL clinical resources.
• Tissue of origin prediction: In cases where a cancer signal is detected, the test predicts the tissue or organ where the cancer signal originated, assisting clinicians in directing follow-up diagnostics.
• Adjunctive screening tool: Intended to complement, not replace, existing single-cancer screening methods.

Pricing

GRAIL's Galleri test is billed directly to healthcare providers, and pricing is not publicly disclosed as a retail cost. The company operates on a custom enterprise pricing model for healthcare organizations. For specific pricing inquiries or to order the Galleri test, healthcare professionals are directed to contact GRAIL directly through their ordering information page.

Common integrations

GRAIL's Galleri test is a clinical diagnostic service, not a platform with publicly available developer APIs or SDKs for direct software integration. Its integration within healthcare systems typically occurs at the workflow level, where healthcare providers order the test, collect samples, and receive results through established clinical laboratory interfaces. Information regarding direct technical integrations with Electronic Health Record (EHR) systems or other clinical software platforms is not publicly detailed by GRAIL. The company's focus is on providing the test and clinical support for its use by medical professionals.

Alternatives

• Exact Sciences: Known for Cologuard, a non-invasive colon cancer screening test, and other cancer diagnostics.
• Guardant Health: Offers liquid biopsy tests like Guardant360 for advanced cancer patients and LUNAR-2 for early cancer detection.
• Freenome: Developing blood tests for early cancer detection and precision oncology, also utilizing multi-omics platforms.

Getting started

GRAIL's Galleri test is a clinical service ordered by healthcare professionals. There is no direct developer API or SDK for programmatic interaction. The process for utilizing the Galleri test involves clinical ordering and laboratory processing. The following outlines the general steps for a healthcare professional to order the test:

// This is a conceptual representation as there is no direct code-based API interaction.
// Healthcare professionals initiate the process through clinical prescription and sample collection.

// Step 1: Healthcare professional determines patient eligibility
function checkPatientEligibility(patientAge, riskFactors) {
  // Patient is generally asymptomatic and at elevated risk, typically over 50 years old.
  if (patientAge >= 50 || riskFactors.includes('high_cancer_risk')) {
    return true; // Eligible for Galleri test as an adjunct to standard screening
  } else {
    return false;
  }
}

// Step 2: Order the Galleri test
function orderGalleriTest(patientId, referringPhysicianId) {
  // This typically involves filling out a requisition form provided by GRAIL
  // and sending it to GRAIL's CLIA-certified laboratory.
  console.log(`Ordering Galleri test for patient ID: ${patientId} by physician: ${referringPhysicianId}`);
  // The actual order submission is a clinical process, not an API call.
  // Example: Submitting a digital or paper requisition form to GRAIL.
  return {
    orderStatus: 'Pending Sample Collection',
    requisitionId: 'REQ' + Math.floor(Math.random() * 1000000)
  };
}

// Step 3: Collect blood sample
function collectSample(patientId, requisitionId) {
  // A standard venipuncture is performed according to GRAIL's instructions.
  console.log(`Collecting blood sample for patient ID: ${patientId} under requisition: ${requisitionId}`);
  // Sample is then packaged and shipped to GRAIL's lab.
  return { success: true, sampleCollectedDate: new Date().toISOString() };
}

// Step 4: Receive and interpret results
function receiveResults(requisitionId) {
  // Results are typically returned to the ordering physician within a specified timeframe
  // via secure clinical channels (e.g., electronic portal, fax, mail).
  // The physician then interprets the 'Cancer Signal Detected' or 'No Cancer Signal Detected' result
  // and the 'Predicted Tissue of Origin' if a signal is present.
  console.log(`Awaiting results for requisition: ${requisitionId}`);
  // Example of a hypothetical result structure:
  // { 
  //   requisitionId: requisitionId,
  //   result: 'Cancer Signal Detected',
  //   predictedTissueOfOrigin: 'Pancreas',
  //   confidenceScore: 0.92,
  //   reportDate: '2026-05-20'
  // }
}

// Example Workflow:
const patientIsEligible = checkPatientEligibility(62, []);
if (patientIsEligible) {
  const order = orderGalleriTest('PAT456', 'DR789');
  if (order.orderStatus === 'Pending Sample Collection') {
    collectSample('PAT456', order.requisitionId);
    receiveResults(order.requisitionId);
  }
}

Healthcare professionals interested in learning more about the Galleri test or initiating the order process can find detailed clinical resources and ordering information on the GRAIL website for healthcare professionals. Further insights into the broader landscape of liquid biopsy and its implications for early cancer detection can be found in publications by research organizations such as Deloitte's analysis on liquid biopsy technology.